copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
bosulif 400 mg
abacus medicine a/s - bosutinibmonohydrat - tablett, filmdrasjert - 400 mg
utrogestan 300 mg
besins healthcare ireland limited (1) - progesteron - vaginalkapsel, myk - 300 mg
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
tolvaptan teva b.v. 30 mg / 90 mg
teva b.v. - tolvaptan - tablett - 30 mg / 90 mg
tolvaptan teva b.v. 30 mg / 60 mg
teva b.v. - tolvaptan - tablett - 30 mg / 60 mg
tolvaptan teva b.v. 45 mg / 15 mg
teva b.v. - tolvaptan - tablett - 45 mg / 15 mg
bosulif 100 mg
2care4 aps - bosutinibmonohydrat - tablett, filmdrasjert - 100 mg
bosulif 400 mg
2care4 aps - bosutinibmonohydrat - tablett, filmdrasjert - 400 mg
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.